Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: jayt who wrote (17451)	2/9/2006 6:34:58 PM
From: Crossy	Read Replies (1) \| Respond to of 37387

Jayt.. some comments from an investor NOT in bed with biotechs at the moment <g> IYXI.OB is quite interesting.. it's a "drug delivery" and/or generics/specialty pharma type of company with recurring revenue already. Way lower risk than classic biotech.. I would take a look at that one.. hope this helps CROSSY

To: jayt who wrote (17451)	2/9/2006 8:12:22 PM
From: fedman	Read Replies (1) \| Respond to of 37387

Thanks. I will look at them with Crossy's insights in mind. I will say that regarding my two picks (YMI and NERX) that the tricky part is that I'm relying on the expertise of others regarding the products coming out of the pipeline. The companies financial condition does not play into my "model". YMI is from my brother who works at medarex. He's a Ph.d. in Genetics from Harvard and works with in drug development on the business side. The second, NERX is because of the manager of the MPM bioequities hedge fund, who I believe would never gamble such a stake on a shot in the dark. With big pharma, I'm able to read up and do more research, with the little miracle drug plays, it's just flying by the seat of my pants. Thanks again for the info.